» Articles » PMID: 15093539

Insights into ErbB Signaling from the Structure of the ErbB2-pertuzumab Complex

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2004 Apr 20
PMID 15093539
Citations 453
Authors
Affiliations
Soon will be listed here.
Abstract

We have determined the 3.2 A X-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also known as 2C4 or Omnitarg. Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling. The ErbB2-pertuzumab structure, combined with earlier mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction. To analyze the ErbB2 side of the interface, we have mutated a number of residues contacting pertuzumab and examined the effects of these mutations on pertuzumab binding and ErbB2-ErbB3 heterodimerization. We have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization.

Citing Articles

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.

de Moraes F, de Castro Ribeiro C, Pessoa F, Chaves J, de Souza A, Di Felipe Avila Alcantara D Breast Cancer Res. 2025; 27(1):39.

PMID: 40089780 DOI: 10.1186/s13058-025-01989-9.


Emerging importance of HER3 in tumorigenesis and cancer therapy.

Garrett J, Tendler S, Feroz W, Kilroy M, Yu H Nat Rev Clin Oncol. 2025; .

PMID: 40087402 DOI: 10.1038/s41571-025-01008-y.


Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis.

Zhang Y, Shang H, Zhang J, Jiang Y, Li J, Xiong H Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006075 PMC: 11859690. DOI: 10.3390/ph18020262.


Engineering IGF2 for Lysosome-targeting chimeras development to target drug-resistant membrane proteins in tumor therapy.

Pan Y, Xiang Q, Deng K, Anwar M, Wang L, Wang Y Protein Sci. 2025; 34(3):e70051.

PMID: 39969096 PMC: 11837023. DOI: 10.1002/pro.70051.


HER2-Positive Breast Cancer Treatment and Resistance.

Veeraraghavan J, De Angelis C, Gutierrez C, Liao F, Sabotta C, Rimawi M Adv Exp Med Biol. 2025; 1464():495-525.

PMID: 39821040 DOI: 10.1007/978-3-031-70875-6_24.